Integrated Research Organization & Global Consortium
Advancing the science of prostate cancer clinical trials
The PCCTC is an integrated research organization (IRO) and global clinical consortium formed to address critically unmet needs in prostate cancer. We design, implement, and complete innovative, process-driven clinical studies that translate scientific discoveries into improved standards of care.
What we do
A full-service partner, from concept to close-out
The PCCTC is changing how prostate cancer therapies and biomarkers are developed. Our unique infrastructure enables transparent project co-development between investigators, clinical research sites, and industry partners.
Project Management
From concept to close-out, the PCCTC's Clinical Operations team ensures studies are completed on time and on budget, facilitating efficient, transparent study management between industry partners, investigators and participating sites, and external vendors.
Learn moreAdvisory Board
PCCTC Advisory Boards are composed of the nation's leading prostate cancer investigators. Effective development of new therapies draws on their expertise in drug development and their unique insights into the prostate cancer scientific landscape.
Learn moreContracts and Budgets
The PCCTC offers a suite of budgeting and contracting tools to expedite study activation. Our contract templates let us negotiate consistent terms of confidentiality, data ownership, publication, and intellectual property across institutions and industry.
Learn moreRegulatory
Proper management of regulatory affairs can dramatically shorten the time it takes to bring safe and effective products to market. The PCCTC coordinates the intricate details of regulatory document management throughout a project's lifecycle, serving as a single point of contact for industry partners and investigators.
Learn moreMedical Communications
The PCCTC offers numerous value-added medical communications services throughout a project's lifecycle. Dedicated staff collaborate directly with investigators, industry partners, regulatory agencies, and publishers to ensure rapid and reliable content production.
Learn moreClinical Data Management
A modern, standards-driven approach to data management delivers the secure, high-quality, rapid results today's prostate cancer trials require. Our workflows follow Good Clinical Data Management Practices and the latest FDA, ICH GCP, and GDPR requirements, leveraging Medidata Rave (EDC) and reusable CDISC-conformant libraries.
Learn moreStatistical Programming and Analysis
PCCTC biostatisticians and statistical programmers are involved at every stage of study planning and execution — from protocol and statistical analysis plans and data collection design through ongoing data-quality monitoring and reporting checkpoints — combining modern computing practices with strict GxP compliance.
Learn moreCorrelative Science and Laboratory Services
Accurate, reliable, reproducible lab results are essential for patient monitoring, regulatory approvals, reimbursement, and drug discovery. Driven by cutting-edge research at our contracted academic medical centers and biopharmaceutical partners, our capabilities meet the rigorous demands of today's drug development.
Learn moreData Science
In close collaboration with PCCTC Data Management and the Biostatistics Service at Memorial Sloan Kettering Cancer Center, our Data Science team applies programming best practices within a modern technology stack to streamline, scale, and enhance the reproducibility of the consortium's analytics and reporting pipelines.
Learn moreOur expertise
Internationally recognized leaders in prostate cancer
PCCTC investigators come from the nation's top academic medical centers, where they are actively engaged in world-class translational research. They developed the universally adopted clinical states model of prostate cancer and led the endpoint-validation efforts behind PCWG2, PCWG3, and PCWG4.
Meet the consortium- Over 200 participating clinical research sites worldwide
- Co-development of novel therapies and predictive biomarkers
- Leadership in trial design, endpoints, and imaging standards
- A collaborative culture spanning academia and industry
Study portfolio
Featured studies
Our trials span the entire prostate cancer disease continuum, strategically aligned with the consortium's pathway-based scientific programs.
IRONMAN: International Registry for Men With Advanced Prostate Cancer
NCT03151629Visit study Germline registryPROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
NCT04995198Visit study PCCTC-sponsoredTALENT: A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate
NCT06844383View studyLatest news
From the consortium
Partner with the PCCTC
Our team provides full-service study management and functional service provider support, accelerating the activation, accrual, and completion of multicenter clinical studies.
Contact us